Insmed to Present at Two October Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall St struggles for direction as rate uncertainty offsets Amazon jump
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Wall Street ends sharply higher, lifted by soaring Microsoft
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Insmed (INSM) PT Raised to $35 at Credit Suisse Following FDA Approval of Arikayce
October 1, 2018 8:45 AM EDTCredit Suisse analyst Martin Auster raised the price target on Insmed (NASDAQ: INSM) to $35.00 (from $33.00) while maintaining a Outperform rating following an FDA announcement that it has approved Arikayce for the treatment of refractory NTM MAC, in line with the FDA AdCom... More
